Cytokinetics INC Form 4 insider transactions

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised 3,500 stock options and sold the resulting shares.

Cytokinetics Director Edward M. Kaye sold 2,933 shares of common stock on June 1, 2026, pursuant to a Rule 10b5-1 trading plan.

EVP and Chief Commercial Officer Andrew Callos exercised 15,000 stock options and sold the resulting shares.

Director B. Lynne Parshall sold 5,000 shares of Cytokinetics Inc. common stock on June 1, 2026, at a price of $74.08 per share.

Cytokinetics President and CEO Robert I. Blum sold 7,500 shares of common stock at an average price of $77.21.

Director Muna Bhanji acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Director James M. Daly acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.

Director Robert Arthur Harrington acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Director John T. Henderson acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Director Edward M. Kaye acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.

Director B. Lynne Parshall acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Director Robert E. Landry acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.

Director Wendell Wierenga acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Director Nancy Wysenski acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, acquired 3,500 shares of common stock and sold 3,500 stock options.

Cytokinetics Inc. reports that President & CEO Robert I. Blum acquired 7,500 shares of common stock on May 14, 2026, for $77.92 per share.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised 3,500 stock options and sold the resulting shares.

Cytokinetics Director Wendell Wierenga engaged in stock transactions, acquiring shares via an option exercise and subsequently selling a portion of his holdings.

Cytokinetics EVP, Chief Financial Officer, Lee Sung, reported a transaction involving the purchase of common stock.

Andrew Callos, EVP and Chief Commercial Officer at Cytokinetics Inc., sold 11,333 shares of common stock on May 5, 2026, under a pre-arranged 10b5-1 trading plan.

Cytokinetics EVP Andrew Callos acquired company stock and disposed of stock options on May 1, 2026, according to a Form 4 filing.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised options and sold 3,500 shares of common stock.

Director Nancy Wysenski acquired 95 shares of Cytokinetics common stock through the company's Director Equity in Lieu of Cash Retainer Program.

Director Wendell Wierenga acquired 95 shares of Cytokinetics common stock as part of a director equity compensation program.

Director Edward M. Kaye acquired 191 shares of Cytokinetics common stock as part of a director equity compensation program.

Director John T. Henderson acquired 325 shares of Cytokinetics common stock through the company's equity-in-lieu-of-cash program.

Director Robert Arthur Harrington acquired 191 shares of Cytokinetics common stock through the company's Director Equity in Lieu of Cash Retainer Program.

Director James M. Daly acquired 191 shares of Cytokinetics common stock as part of the company's Director Equity in Lieu of Cash Retainer Program.

EVP and Chief Commercial Officer Andrew Callos sold 7,449 shares of Cytokinetics common stock on April 15, 2026.

Cytokinetics President and CEO Robert I. Blum sold 7,500 shares of common stock on April 15, 2026.